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Received November 29, 2012; accepted May 16, 2013AbstractGlutaric aciduria type 1 (GA1) is a rare, inherited mitochondrial disorder that results from deficiency of mitochondrial glutaryl-CoA de-
hydrogenase. Most patients develop neurological dysfunction early in life, which leads to severe disabilities. We present a 37-month-old girl with
GA1 manifested as macrocephaly and hypotonia who received comprehensive dental restoration surgery under general anesthesia with sevo-
flurane. She was placed on specialized fluid management during a preoperative fasting period and anesthesia was administered without com-
plications. All the physiological parameters, including glucose and lactate blood levels and arterial blood gas were carefully monitored and
maintained within normal range perioperatively. Strategies for anesthetic management should include prevention of pulmonary aspiration,
dehydration, hyperthermia and catabolic state, adequate analgesia to minimize surgical stress, and avoidance of prolonged neuromuscular
blockade. We administered general anesthesia with sevoflurane uneventfully, which was well tolerated by our patient with GA1. Additionally,
communication with a pediatric geneticist and surgeons should be undertaken to formulate a comprehensive anesthetic strategy in these patients.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Glutaric aciduria type 1 (GA1) is a rare autosomal reces-
sive disorder with an estimated prevalence of 1:100,000
newborns in a Taiwanese study.1 This disorder involves a
deficiency of mitochondrial glutaryl-CoA dehydrogenase
(GCDH), which results in an inborn error of lysine, hydrox-
ylysine, and tryptophan metabolism.2 Excessive organic acidsConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Asssuch as glutaric acid, 3-hydroxyglutaric acid, and glutaconic
acid accumulate in the brain and lead to neuronal damage,
lymphocyte infiltration, elevated concentrations of inflam-
matory cytokines and nitric oxide, glial proliferation, atrophy
of striatal neurons, and neurologic dysfunction.3 Though
newborn screening and early treatment can prevent such
neurological damage in most patients with GA1, routine
treatment does not protect against the encephalopathic crisis
that can be precipitated by fever, gastroenteritis (GE), and
surgery.4 Therefore, intensified emergency treatment target-
ing prevention or reversal of encephalopathic crisis has been
recommended to commence without delay and performed
aggressively, especially during surgical intervention.5 How-
ever, there are only a few reports regarding general anesthesia
conducted under either total intravenous anesthesia (TIVA)ociation. All rights reserved.
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tional anesthesia with sevoflurane for reduction of hip
dislocation in patients with GA1.6,7 We report here the
anesthetic management with sevoflurane for a 37-month-old
girl with GA1 undergoing comprehensive dental restoration
surgery.1.1. Patient consent statementWritten informed consent was signed and obtained from the
patient's parent. The authors assured the patient's parent that
the information will be published without the patient's name
attached and every attempt made to maintain anonymity.
2. Case report
A 37-month-old girl with GA1 who weighed 19 kg and who
presented with macrocephaly and hypotonia was scheduled for
comprehensive dental restoration surgery for treatment of
multiple dental caries. Because glutaric aciduria was suspected
during neonatal genetic screening, she was referred to our
hospital for diagnosis and treatment on postnatal Day 10. The
diagnosis was confirmed by the large amount of urinary glu-
taric acid along with elevated serum glutarylcarnitine. The
patient was treated with oral carnitine supplementation and
protein restriction with special formula milk (XLYS, LOW
TRY Analog). Magnetic resonance imaging of the brain per-
formed under sedation anesthesia with intravenous midazolam
and thiopental at 3 months of age showed prominent extra-
axial cerebrospinal fluid space, marked widening of Sylvian
fissures and middle cranial fossa, and relative loss of bilateral
frontotemporal volume. The patient had a history of repeated
upper respiratory tract infection (URI) and GE at her 5-, 9-,
and 13-month check-ups. No acute neuromotor deterioration
was present, and psychomotor development assessed by the
age of 7 months showed no psychological delay except mild
motor delay. On preanesthetic clinical examination, the patient
was asymptomatic except for macrocephaly, with an occipi-
tofrontal circumference of 53 cm (>97th percentile for age),
and hypotonia.2.1. Anesthetic managementDuring the preoperative fasting period, the patient
received intravenous fluid therapy with 10% dextrose in
0.33% saline with potassium chloride (KCl, at a concentra-
tion of 6 mEq/500 mL) infused at 60 mL/hour and 20%
intralipid infused at 6 mL/hour. After routine monitors and
preoxygenation were applied, anesthesia was induced with
atropine (0.01 mg/kg), thiamylal (5 mg/kg), fentanyl (2 mg/
kg), and cisatracuium (0.2 mg/kg) under parental accompa-
niment, and manual ventilation was applied using the Sellick
maneuver. The patient underwent nasal intubation intubated
with a 5-mm cuffed endotracheal tube, and anesthesia was
maintained with sevoflurane (1e1.5 minimum alveolar
concentration) in 50% oxygen and cisatracurium 0.03 mg/kg
every 60 minutes. A 24-gauge arterial catheter was insertedinto the left radial artery. Mechanical ventilation was tar-
geted at maintaining an end-tidal carbon dioxide level of
35e40 mmHg. The patient's body temperature was main-
tained between 36C and 37C with a warming blanket and
intravenous fluid therapy was continued until oral intake
resumed. All the physiological parameters, blood levels of
glucose and lactate, and arterial blood gas were closely
monitored and maintained within normal range perioper-
atively. Ketorolac (0.5 mg/kg) was intravenously adminis-
tered 30 minutes before the end of the surgical procedure,
which was 5 hours in duration. Neuromuscular blockade was
reversed with neostigmine and the patient was extubated
without difficulty in the operating room. The patient resumed
food intake 8 hours later and was discharged uneventfully
the next day.
3. Discussion
GA1 is a rare genetic disorder caused by GCDH deficiency,
with organic acid accumulation in the brain and neuro-
degeneration. Secondary carnitine deficiency will occur as the
accumulated organic acids are detoxified by carnitine. Patients
with GA1 often present with macrocephaly at birth or dystonia
shortly afterward. Brain imaging performed shortly after birth
usually shows frontoparietal atrophy with widening of Sylvian
fissures and arachnoid cysts, and the brain is vulnerable to
head trauma that can lead to acute subdural or retinal hem-
orrhage.3,7 Brain atrophy and neuronal loss following injury to
the basal ganglia may be accompanied by symptoms such as
dystonia, spasticity, rigidity, posture impairment, and com-
plications that impair oral feeding and communication.3,7 Pa-
tients usually present with an episode of acute infection
accompanied by fever and dehydration, and may become hy-
potonic, lose head control, and have choreoathetosis similar to
seizures. Hypotonia slowly improves over weeks but is then
replaced with rigidity and dystonia; therefore, patients may
develop severe disability and remain wheelchair-bound. These
children develop decreased coordination of swallowing
movements and are prone to pulmonary aspiration. Some pa-
tients may even require nasogastric tube feeding and later
require permanent gastrotomy.4 Although these patients have
difficulty taking or performing tasks, cognition is usually
normal. Acute neurological deterioration or encephalopathic
crisis, marked by spasm, dystonia, and lethargy, is caused by
glutaric acid passage through the bloodebrain barrier.7,8 Pa-
tients with GA1 will develop neurological damage with
complications and reduced life expectancy following
encephalopathic crisis, and both pneumonia and encephalo-
pathic crisis are the most common causes of death in these
patients.3,4,8
With neonatal screening, early routine treatment with
carnitine supplement special restriction diet, and neuro-
protective emergency treatment, most patients with GA1
may have protection against encephalopathic crisis and
possibly lead a normal life.7,9e11 Screening identifies
elevated glutarylcarnitine in blood spots, and newborns with
positive screening results are then confirmed by urinary
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genetic mutation identification. Carnitine supplementation in
combination with dietary treatment with protein restriction
supplemented with lysine-free special formulas are all
crucial for a good neurological outcome.9 Emergency treat-
ment to prevent encephalopathic crisis, including preventing
catabolism by administering high-energy intake, reducing
organic acid production by transient reduction or omission of
natural protein intake, avoiding secondary carnitine deple-
tion, and maintaining normal fluid, electrolyte, and pH sta-
tus, should be started when patients with GA1 are at risk or
during surgery.11
It is important for patients with GA1 to prevent acute
encephalopathic crises while undergoing surgery.8,11 Strate-
gies for anesthetic management should include prevention of
pulmonary aspiration, dehydration, hyperthermia, and cata-
bolic state, adequate analgesia to minimize surgical stress, and
avoidance of prolonged neuromuscular blockade. Dehydration
can be prevented by maintaining normal fluid and electrolyte
status via intravenous fluid as soon as fasting started, and
prevention of catabolic state can be achieved by high-energy
intake. An intravenous regimen consisting of 10% dextrose
in 0.33e0.5 normal saline with KCl supplied at a volume
1.5e2 times the daily amount and intralipid 20% supple-
mented at a rate of 10% of intravenous fluid therapy has been
proposed.8 In the current case, we had continuously adminis-
tered intravenous high-caloric fluid therapy until the resump-
tion of oral intake to prevent dehydration, hypoglycemia, and
catabolism. We applied the Sellick maneuver during mask
ventilation and endotracheal intubation to avoid pulmonary
aspiration as suggested by Hernandez-Palazon et al,6 but we
chose a standard intubation procedure instead of rapid
sequence intubation to minimize stress response to endotra-
cheal intubation.
Glutaric aciduria is a disorder caused by a deficiency of the
mitochondrial enzyme, and Driessen et al12 reported no major
anesthesia-related complications or adverse events in children
with mitochondrial disorders undergoing muscle biopsy under
general anesthesia with sevoflurane. Footitt et al13 also re-
ported that there were no episodes of malignant hyperthermia
attributable to general anesthesia with inhalation anesthetics in
patients with mitochondrial disorder. Furthermore, carnitine is
an essential cofactor in the transport of long-chain fatty acids
into the mitochondria and plays a critical role in fatty acid
oxidation, and secondary carnitine deficiency is suggested to
play an important role in the neuropathogenesis of GA1.
Propofol can provide lipid overload and inhibit oxidative
phosphorylation, carnitine palmitoyltransferase transport of
long-chain fatty acids, and b-oxidation of fatty acid in mito-
chondria; therefore, it raises concern about the presence of
propofol infusion syndrome and severe metabolic acidosis,
especially in patients with mitochondrial disorder, carnitine
deficiency, and inadequate carbohydrate intake.14e16 There-
fore, we chose to induce with thiamylal and maintain general
anesthesia with sevoflurane rather than with propofol for both
induction and maintenance of general anesthesia in the current
case, and general anesthesia was safely conducted withsevoflurane. Another concern regarding the anesthetic man-
agement of patients with GA1 is increased sensitivity and
prolonged response to neuromuscular blocking agents.
Administration of rocuronium with a bolus dose followed by
either a continuous infusion or not had been used in patients
with GA1 undergoing cerebrospinal fluid shunting and
neurogenic hip dislocation procedures, and intraoperative
acceleromyography monitoring was applied to avoid residual
or sustained neuromuscular blockade.6,7 Despite the absence
of intraoperative neuromuscular monitoring in the current
case, we used cisatracurium to avoid prolonged muscle
relaxation and neostigmine to antagonize neuromuscular
blockade at the conclusion of surgery. The patient recovered
muscle power and woke up a few minutes later. Tracheal
extubation was carried out when the patient was awake with
sustained eye opening, stable vital signs, adequate sponta-
neous respiration, and presence of airway protective reflexes
(i.e., swallow, gag, and cough) without clinically residual
neuromuscular blockade or prolonged recovery time.
Furthermore, to manage surgical stress and pain, we admin-
istered fentanyl during anesthetic induction and ketolorac
30 minutes before the end of surgery. Our patient recovered
without complications with rapid extubation at the end of
surgery, and was not agitated and did not complain of pain in
the postanesthesia recovery room.
It is crucial to have a thorough understanding of the path-
omechanism and clinical manifestation of GA1 while man-
aging these patients. It is also important to have timely
communication with a pediatric geneticist and surgeons ahead
of elective surgery, to formulate a comprehensive anesthetic
strategy in these patients.5 Anesthetic management with stra-
tegies to prevent the acute encephalopathic crises during and
after surgery is mandatory. In conclusion, we administered
general anesthesia with sevoflurane uneventfully, which was
well tolerated in our patient with GA1.
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